Form 4: BioMarin Executive Charles Guyer Reports Stock Transactions

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

Summary

• On March 14, 2025, Charles Greg Guyer disposed of 20,127 shares of BioMarin common stock at a price of $69.44.
• This disposal was likely to cover tax obligations related to vesting restricted stock units.
• On March 17, 2025, Guyer acquired 13,310 shares of common stock through restricted stock units.
• Also on March 17, 2025, Guyer acquired options to purchase 30,880 shares of common stock at an exercise price of $71.55, vesting in installments starting March 17, 2026.
• Following these transactions, Guyer directly owns 80,838 shares of BioMarin common stock and options to purchase 30,880 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. There's no indication of significant positive or negative news.

Positives

• The grant of restricted stock units and stock options to a key executive suggests the company is incentivizing long-term performance.
• Guyer's continued direct ownership of 80,838 shares demonstrates a continued investment in the company's future.

Negatives

• The disposal of 20,127 shares, while likely for tax purposes, could be perceived negatively by some investors if not properly understood.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.
• The vesting schedule of the stock options could influence the executive's decisions over the next several years.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options implies a multi-year commitment from the executive.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical industry to align management's interests with those of shareholders. These grants are designed to incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, similar to companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
• The vesting schedule of the options (12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter) is a typical vesting structure designed to retain executives over a four-year period.
• The size of the option grant and restricted stock units should be compared to BioMarin's market capitalization and the executive's role within the company to determine if it is in line with industry norms.

Stakeholder Impact

• The transactions have a minor impact on shareholders, primarily through potential dilution from the exercise of stock options in the future.
• The executive's continued ownership of a significant number of shares aligns his interests with those of shareholders.

Key Dates